| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026134 | Ophthalmology | 2014 | 10 Pages |
Abstract
Even after considering the potential for differences in risks of serious adverse events and therapeutic effectiveness, bevacizumab confers considerably greater value than ranibizumab for the treatment of neovascular macular degeneration.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Joshua D. MD, MS, Paula Anne MD, MS, Tavag MPH, Paul P. MD, JD, David W. PhD,